|
|
|
| Application of Thinprep cytology test combined with high-risk human papilloma virus detection for screening cervical cancer |
| The Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital), Chengdu, Sichuan Province, 610057 |
|
|
|
|
Abstract To investigate the application effect of Thinprep cytology test (TCT) combined with high-risk human papillomavirus (HR-HPV) detection for screening cervical cancer. Methods: The clinical data of 3,500 women who received cervical cancer screening from January 2022 to May 2023 were selected as the study subjects. With the pathological diagnosis as the gold standard, the diagnostic efficacy of TCT, HR-HPV detection, and the combination of TCT and HR-HPV detection of the women for their cervical cancer was analyzed by receiver operating characteristic (ROC) curve. Results: Among 3500 women, there were 33 cases with cervical cancer, 112 cases with cervical intraepithelial neoplasia (CIN)II and CINI II, 267 cases with CIN I and 3,088 cases with cervicitis. ROC curve analysis results showed that the area under the curve (AUC) of the TCT of the women for screening their cervical cancer was 0.741, with the sensitivity of 48.5% and the specificity of 99.7%. The AUC of the HR- HPV detection of the women for screening their cervical cancer was 0.769, with the sensitivity of 54.6% and the specificity of 99.3%. When the women diagnosed as cervical cancer based on the TCT or the HR-HPV detection with positive result, the AUC of the TCT combined with the HR-HPV detection of the women for screening their cervical cancer was 0.980, with the sensitivity of 97.0% and the specificity of 99.1%. Conclusion: TCT combined with HR-PHV detection of the women for screening their cervical cancer has higher diagnostic efficacy, which can improve the diagnostic sensitivity and has higher clinical value for screening the cervical cancer and the precancerous lesions of the women.
|
|
|
|
|
|
|
|
|
